Global Scans · Pharmaceuticals · Weekly Summary

• [New] Scientists at the University of California, San Diego School of Medicine have developed an investigational drug that could provide a new treatment for metabolic dysfunction-associated steatohepatitis. SciTechDaily
• [New] The FDA granted its first-ever acceptance to waive clinical efficacy studies (CES) for a monoclonal antibody biosimilar earlier this month, marking a major shift that could lower drug costs, speed up approvals and broaden access to affordable treatments worldwide. Managed Healthcare Executive
• [New] Quantum computing's potential is no longer theoretical; 2025 sees it revolutionizing fields like drug discovery and financial modeling. WebProNews
• [New] In a move that could reshape drug discovery, researchers at Harvard Medical School have designed an artificial intelligence model capable of identifying treatments that reverse disease states in cells. News-Medical
• [New] Quantum-AI hybrid systems drive breakthroughs in drug discovery and finance, while a 3:1 talent gap in quantum roles (250K needed by 2030) forces upskilling initiatives and industry-led training programs. Ainvest
• [New] The US Food and Drug Administration has authorized updated COVID-19 vaccines for fall 2025, limiting eligibility to adults aged > = 65 years and individuals with at least one underlying medical condition that increases risk of severe illness. ContagionLive
• [New] Avery Dennison will launch new UV Barrier solutions - a range of clear film pharmaceutical labels that provide a functional barrier while protecting potentially life-saving medicines from degradation caused by UV light. Packaging Technology Today
• [New] Instead of ~8 years, a biosimilar might reach approval in ~5-6 years. Mabion S.A.
• [New] Niazi's biosimilar application for Stelara will be the first filed with the FDA that does not require any clinical testing, marking a precedent-setting regulatory breakthrough. Pharmacy Times
• [New] Pharmaceutical firm Sanofi in Paris suggests that the acne vaccine it is developing could yield more than $2 billion per year in revenue. Scientific American
• [New] Sanofi has 12 new drug candidates, including Amlitelimab and Frexalimab, as next-generation drugs and aims to achieve annual sales of more than €1 billion by 2030. ABITA LLC&MARKETING JAPAN
• [New] If a new blockbuster drug that surpasses Dupixent becomes a reality, it could change the world's medical map by 2030. ABITA LLC&MARKETING JAPAN

Last updated: 16 September 2025